Want to see HK:9960 full AI Analyst Report?
Top Page
Kindstar Globalgene Technology, Inc.
(9960)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$0.93
▼(-20.94% Downside)
Action:Reiterated
Date:04/30/26
The score is held back primarily by sustained revenue contraction and continued net losses, despite a relatively strong low-leverage balance sheet and an encouraging swing to positive operating and free cash flow in 2025. Technicals and valuation signals are broadly neutral, offering limited near-term support.
Positive Factors
Conservative balance sheet
A low debt-to-equity ratio (~0.16 in 2025) and a sizable equity base give Kindstar financial resilience versus peers. This structural strength reduces default risk, preserves liquidity, and provides optionality to fund operations or targeted investments over the next several months.
Negative Factors
Sustained revenue decline
Three consecutive years of top-line contraction point to persistent demand loss, pricing pressure, or client attrition. Continued revenue erosion undermines scale economics in labs, makes fixed-cost absorption harder, and limits the path to durable profitability without a clear revenue turnaround.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
A low debt-to-equity ratio (~0.16 in 2025) and a sizable equity base give Kindstar financial resilience versus peers. This structural strength reduces default risk, preserves liquidity, and provides optionality to fund operations or targeted investments over the next several months.
Read all positive factors
Kindstar Globalgene Technology, Inc. (9960) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.02B
Dividend Yield2.02%
Average Volume (3M)956.95K
Price to Earnings (P/E)―
Beta (1Y)0.68
Revenue Growth0.69%
EPS Growth-1.39%
CountryHK
Employees3,011
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,041,326,700
10 Day Avg. Volume603,200
30 Day Avg. Volume956,950
Financial Highlights & Ratios
PEG Ratio-6.54
Price to Book (P/B)0.37
Price to Sales (P/S)1.07
P/FCF Ratio22.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kindstar Globalgene Technology, Inc. Business Overview & Revenue Model
Company Description
Kindstar Global (Beijing) Technology, Inc. is a prominent provider of highly specialized diagnostic services to healthcare institutions across China. Beyond just diagnostics, the company extends its expertise to support medical research, clinical ...
How the Company Makes Money
Kindstar Globalgene Technology, Inc. primarily makes money by providing diagnostic testing services on a fee-for-service basis, charging healthcare providers (or other payors) for laboratory analyses performed on patient samples. Key revenue strea...
Kindstar Globalgene Technology, Inc. Financial Statement Overview
Summary
Income Statement
36
Negative
Balance Sheet
70
Positive
Cash Flow
48
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 933.57M | 927.57M | 967.26M | 1.39B | 930.67M |
| Gross Profit | 411.38M | 439.56M | 451.13M | 603.05M | 485.77M |
| EBITDA | -95.69M | -117.24M | 126.38M | 150.72M | -1.39B |
| Net Income | -58.74M | -54.59M | 41.29M | 75.46M | -1.45B |
Balance Sheet | |||||
| Total Assets | 3.76B | 3.77B | 3.67B | 3.73B | 3.19B |
| Cash, Cash Equivalents and Short-Term Investments | 1.56B | 1.66B | 2.03B | 2.00B | 2.15B |
| Total Debt | 438.12M | 398.36M | 194.29M | 199.86M | 18.19M |
| Total Liabilities | 969.17M | 950.51M | 774.23M | 871.62M | 464.15M |
| Stockholders Equity | 2.73B | 2.78B | 2.87B | 2.83B | 2.72B |
Cash Flow | |||||
| Free Cash Flow | 43.60M | -179.57M | -189.65M | -102.90M | -220.23M |
| Operating Cash Flow | 91.17M | -44.12M | -14.78M | 21.41M | 68.03M |
| Investing Cash Flow | -36.85M | -1.21B | 854.92M | -1.35B | -666.06M |
| Financing Cash Flow | -39.49M | 144.63M | -82.83M | 97.64M | 1.59B |
Kindstar Globalgene Technology, Inc. Technical Analysis
Neutral
1.17
Price Trends
1.01
Negative
1.03
Negative
1.11
Negative
Market Momentum
>-0.01
Positive
50.00
Neutral
55.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9960, the sentiment is Neutral. The current price of 1.17 is above the 20-day moving average (MA) of 0.97, above the 50-day MA of 1.01, and above the 200-day MA of 1.11, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 50.00 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:9960.
Kindstar Globalgene Technology, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$109.69B | 17.60 | 9.11% | ― | 26.35% | 28.38% | |
54 Neutral | HK$1.40B | 98.57 | 0.48% | 0.49% | -2.63% | ― | |
52 Neutral | HK$5.78B | 116.33 | 0.60% | ― | -9.81% | -72.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$1.02B | -14.18 | -2.13% | 2.02% | 0.69% | -1.39% | |
49 Neutral | HK$5.44B | -4.88 | -10.66% | 2.38% | -5.73% | -442.94% | |
42 Neutral | HK$626.93M | -2.04 | -15.15% | ― | 18.62% | 44.24% |
* Healthcare Sector Average
HK:9960
Kindstar Globalgene Technology, Inc.
0.98
-0.27
-21.35%
HK:1951
Jinxin Fertility Group Ltd.
2.02
-0.99
-32.98%
HK:3886
Town Health International Medical Group Ltd.
0.21
-0.03
-10.78%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
9.41
-6.29
-40.06%
HK:6618
JD Health International, Inc.
34.16
-7.79
-18.57%
HK:2453
Concord Healthcare Group Co., Ltd. Class H
0.80
-5.19
-86.64%
Kindstar Globalgene Technology, Inc. Corporate Events
Kindstar Globalgene Grants Employee Share Options Under Post-IPO Scheme
Jun 30, 2026
Kindstar Globalgene Technology, Inc. has granted 50,000 share options to a single employee under its post-IPO share option scheme adopted in 2021, with each option entitling the holder to subscribe for one ordinary share. The grantee is not a dire...
Kindstar Shareholders Approve All AGM Resolutions and Final Dividend
Jun 5, 2026
Kindstar Globalgene Technology, Inc. reported that all resolutions at its 5 June 2026 annual general meeting were passed by shareholders through poll voting. Investors approved the 2025 audited financial statements, re-elected all proposed directo...
Kindstar Adjusts Partnership Term and Fees as Investment Fund Extends to 2029
May 7, 2026
Kindstar Globalgene Technology has announced amendments to a partnership agreement governing an investment fund in which it participates, extending the fund’s overall duration to May 8, 2029. The partnership will now have a three-year invest...
Kindstar Globalgene Sets 2026 AGM to Renew Mandates and Board Line-Up
Apr 24, 2026
Kindstar Globalgene Technology, Inc. has convened its 2026 annual general meeting as a virtual event on 5 June 2026 to review the audited financial statements for the year ended 31 December 2025 and to decide on a series of key governance matters....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.